Probus Surgery Limited 07450536 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of a surgical centre providing specialist day case surgery. Digita Accounts Production Advanced 6.30.9574.0 true false false false 07450536 2024-04-01 2025-03-31 07450536 2025-03-31 07450536 bus:OrdinaryShareClass1 2025-03-31 07450536 core:RetainedEarningsAccumulatedLosses 2025-03-31 07450536 core:ShareCapital 2025-03-31 07450536 core:CurrentFinancialInstruments 2025-03-31 07450536 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07450536 core:FurnitureFittings 2025-03-31 07450536 core:OfficeEquipment 2025-03-31 07450536 core:PlantMachinery 2025-03-31 07450536 bus:SmallEntities 2024-04-01 2025-03-31 07450536 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 07450536 bus:FilletedAccounts 2024-04-01 2025-03-31 07450536 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 07450536 bus:RegisteredOffice 2024-04-01 2025-03-31 07450536 bus:Director1 2024-04-01 2025-03-31 07450536 bus:Director2 2024-04-01 2025-03-31 07450536 bus:Director3 2024-04-01 2025-03-31 07450536 bus:Director4 2024-04-01 2025-03-31 07450536 bus:Director5 2024-04-01 2025-03-31 07450536 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 07450536 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07450536 core:ComputerEquipment 2024-04-01 2025-03-31 07450536 core:FurnitureFittings 2024-04-01 2025-03-31 07450536 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 07450536 core:OfficeEquipment 2024-04-01 2025-03-31 07450536 core:PlantMachinery 2024-04-01 2025-03-31 07450536 core:Subsidiary1 2024-04-01 2025-03-31 07450536 core:Subsidiary1 1 2024-04-01 2025-03-31 07450536 core:Subsidiary1 countries:England 2024-04-01 2025-03-31 07450536 core:Subsidiary2 2024-04-01 2025-03-31 07450536 core:Subsidiary2 1 2024-04-01 2025-03-31 07450536 core:Subsidiary2 countries:England 2024-04-01 2025-03-31 07450536 1 2024-04-01 2025-03-31 07450536 countries:AllCountries 2024-04-01 2025-03-31 07450536 2024-03-31 07450536 core:FurnitureFittings 2024-03-31 07450536 core:OfficeEquipment 2024-03-31 07450536 core:PlantMachinery 2024-03-31 07450536 2023-04-01 2024-03-31 07450536 2024-03-31 07450536 bus:OrdinaryShareClass1 2024-03-31 07450536 core:RetainedEarningsAccumulatedLosses 2024-03-31 07450536 core:ShareCapital 2024-03-31 07450536 core:CurrentFinancialInstruments 2024-03-31 07450536 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 07450536 core:FurnitureFittings 2024-03-31 07450536 core:OfficeEquipment 2024-03-31 07450536 core:PlantMachinery 2024-03-31 07450536 core:Subsidiary1 1 2023-04-01 2024-03-31 07450536 core:Subsidiary2 1 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07450536

Probus Surgery Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

Probus Surgery Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Probus Surgery Limited

Company Information

Directors

Dr G Lin Sin Cho

Dr R Murthy

Dr K Smithson

Dr G E Moon

Mr J S Casey

Registered office

The Surgery
Tregony Road
Probus
Cornwall
TR2 4JZ

 

Probus Surgery Limited

(Registration number: 07450536)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

171,184

178,325

Investments

5

200

200

 

171,384

178,525

Current assets

 

Stocks

11,842

11,842

Debtors

6

409,754

532,270

Cash at bank and in hand

 

1,051,563

682,052

 

1,473,159

1,226,164

Creditors: Amounts falling due within one year

7

(541,192)

(459,043)

Net current assets

 

931,967

767,121

Total assets less current liabilities

 

1,103,351

945,646

Provisions for liabilities

(41,891)

(43,477)

Net assets

 

1,061,460

902,169

Capital and reserves

 

Called up share capital

8

95

95

Retained earnings

1,061,365

902,074

Shareholders' funds

 

1,061,460

902,169

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

 

Probus Surgery Limited

(Registration number: 07450536)
Balance Sheet as at 31 March 2025

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 2 August 2025 and signed on its behalf by:
 

.........................................
Dr G Lin Sin Cho
Director

 

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
The Surgery
Tregony Road
Probus
Cornwall
TR2 4JZ

These financial statements were authorised for issue by the Board on 2 August 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Disclosure of long or short period

The comparative period is for the 9 month period from 1 July 2023 to 31 March 2024.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Tax

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

20% reducing balance

Fixtures and fittings

20% reducing balance

Computer equipment

33% reducing balance

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

 

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 42 (2024 - 39).

 

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4

Tangible assets

Fixtures and fittings
£

Plant and machinery
£

Office equipment
£

Total
£

Cost or valuation

At 1 April 2024

60,203

367,811

142,568

570,582

Additions

639

38,489

3,525

42,653

At 31 March 2025

60,842

406,300

146,093

613,235

Depreciation

At 1 April 2024

24,567

264,668

103,022

392,257

Charge for the year

7,254

28,326

14,214

49,794

At 31 March 2025

31,821

292,994

117,236

442,051

Carrying amount

At 31 March 2025

29,021

113,306

28,857

171,184

At 31 March 2024

35,636

103,143

39,546

178,325

5

Investments

2025
£

2024
£

Investments in subsidiaries

200

200

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

 

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

2025

2024

Subsidiary undertakings

Cornwall Medical Group Limited

The Surgery
Tregony Road
Probus
Truro
Cornwall

England

100 Ordinary shares

100%

100%

Probus Medicines Limited

The Surgery
Tregony Road
Probus
Truro
Cornwall

England

100 Ordinary shares

100%

100%

Subsidiary undertakings

Cornwall Medical Group Limited

The principal activity of Cornwall Medical Group Limited is the provision of specialist medical practice activities.

Probus Medicines Limited

The principal activity of Probus Medicines Limited is operating as a dispensing chemist.

6

Debtors

Current

Note

2025
£

2024
£

Trade debtors

 

224,173

363,675

Amounts owed by related parties

168,962

135,935

Prepayments

 

7,556

32,115

Other debtors

 

9,063

545

   

409,754

532,270

 

Probus Surgery Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

7

Creditors

Creditors: amounts falling due within one year

2025
£

2024
£

Due within one year

Trade creditors

224,574

219,685

Taxation and social security

225,588

195,027

Accruals and deferred income

3,499

4,613

Other creditors

87,531

39,718

541,192

459,043

8

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £0.01 each

9,500

95

9,500

95

       

9

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £773,404 (2024 - £1,346,229).